SEPN: Septerna Inc O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati
Septerna Inc hujayra retseptorlarini nishonga olish orqali endokrin va immun patologiyalari uchun terapiyalarni ishlab chiqish bilan o'z risklarini diversifikatsiya qilmoqda. P/E koeffitsiyentining o'sish sur'atiga nisbati ushbu strategiyani tasdiqlaydi, bunda 0.00 qiymati ushbu darajani xarakterlaydi. GPCR-sfera innovatori sifatidagi ijobiy imij, yaqinda o'tkazilgan IPOdan keyin rahbariyatning kuchli ilmiy bazasi va ventura kapitali ko'magi bilan to'ldirilgan.
Septerna Inc (SEPN) kompaniyasi koʻrsatkichlari kesimi va tahlili
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- kompaniyaning balans qiymati tafsilotlari:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning kapitalga nisbati Septerna Inc|SEPN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi septerna.com|SEPN - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Septerna Corp|SEPN - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli qarz hajmi Septerna|Shoshilinch likvidlik septerna.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
SEPN - Kompaniyaning sof foydasi|Forvard foyda Septerna Inc|SEPN - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning kelajakdagi foydaga nisbati Septerna Pharma|SEPN - PEG multiplikatori|Kompaniya qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati Septerna Corp|SEPN - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|Sirpanuvchi yil uchun bir aksiya uchun foyda Septerna|SEPN - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bir aksiya uchun foydaning yillik o'sishi septerna.com|SEPN - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Septerna Inc
Kompaniyaning umumiy tahlili:SEPN - Septerna, Inc.
PEG koeffitsiyenti foydaning bozor qiymatini uning o'sish sur'ati bilan solishtiradi va qiymatlar birdan pastga tushganda qadrsizlangan aktivlarni aniqlash imkonini beradi. GURU.Markets platformasidagi peg_co metrikasini tahlil qilish orqali investor Septerna Inc. (SEPN) kompaniyasining kapitalizatsiya salohiyatini baholaydi, bu yerda Native GPCR platformasining robotlashtirilishi dori vositalarini ishlab chiqishni tezlashtirib, joriy aksiya narxidan tezroq o'sadigan foyda o'sishi uchun asos yaratadi.
Septerna Inc raqobatchilari
ARGX (argenx N.V.) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori BNTX (BioNTech Group)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Abivax (ABVX)|ADMA - Narxning foydaga va o‘sish sur’atiga nisbati|protagonist-inc.com (PTGX) - Narx-foyda va o‘sish multiplikatori|Immunovant (IMVT) - Narxning foydaga va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori Kiniksa Pharmaceuticals, Ltd.|Narx-foyda va o‘sish multiplikatori GRFS|PEG multiplikatori Adaptive Biotechnologies Inc.|Narxning foydaga va o‘sish sur’atiga nisbati Celldex Therapeutics (CLDX)|auriniapharma.com - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|PEG multiplikatori BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - O‘sish sur’atiga tuzatilgan narx-foyda|DNTH - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Pharvaris Pharma PHVS|ABCL: PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda tourmalinebio.com (TRML)|Narxning foydaga va o‘sish sur’atiga nisbati Precigen|Pharming Group NV - Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori NKTR (Nektar)|Kompaniya qiymatining foyda o‘sish sur’atiga nisbati UPB|PEG multiplikatori ZBIO (Zenas Biopharma Inc)|immunome.com (IMNM) - O‘sish sur’atiga tuzatilgan narx-foyda|GOSS - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti KALV (KalVista Pharma)|Pieris Pharmaceuticals Inc (PVLA) - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sishni hisobga olgan narx-foyda koeffitsiyenti SVRA|RIGL (Rigel Pharmaceuticals) - PEG multiplikatori|PEG multiplikatori anaptysbio.com|Narx-foyda va o‘sish multiplikatori ATXS (Astria Therapeutics, Inc.)|ENGN (enGene Holdings Inc) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori RAPT (RAPT Therapeutics, Inc.)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Aerovate Therapeutics, Inc. (JBIO)|ACRS - Narxning foydaga va o‘sish sur’atiga nisbati|KYTX (kyvernatx.com) - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|TLSA: PEG multiplikatori|Narx-foyda va o‘sish multiplikatori Cabaletta Bio Inc.|Narxning foydaga va o‘sish sur’atiga nisbati Ventyx Bio|Theratechnologies, Inc (THTX) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|PEG multiplikatori AVTX|ELDN - O‘sish sur’atiga tuzatilgan narx-foyda|Narxning foydaga va o‘sish sur’atiga nisbati Agenus Inc. AGEN|CLYM (Climb Bio Inc.) - Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|ZURA - Narxning foydaga va o‘sish sur’atiga nisbati|ATYR (aTyr Pharmaceuticals) - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|adagene.com (ADAG) - Narxning foydaga va o‘sish sur’atiga nisbati|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati IMA (Ikena Oncology)|STTK (Shattuck Labs Inc) - PEG multiplikatori|EQ: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori CNTB|PEG multiplikatori immunic-therapeutics.com (IMUX)|Narxning foydaga va o‘sish sur’atiga nisbati Atara Bio ATRA|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti IFRX|XFOR - Narxning foydaga va o‘sish sur’atiga nisbati|Adicet Bio (ACET) - Narx-foyda va o‘sish multiplikatori|CELU: PEG multiplikatori|INmune Bio Corporation (INMB) - PEG multiplikatori|Narx-foyda va o‘sish multiplikatori BRNS|KZR: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori SABS|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Akari Therapeutics PLC|Narxning foydaga va o‘sish sur’atiga nisbati Enlivex Therapeutics Ltd. ENLV|QTTB - Narx-foyda va o‘sish multiplikatori|GOVX - Narxning foydaga va o‘sish sur’atiga nisbati|edesabiotech.com (EDSA) - Narx-foyda va o‘sish multiplikatori|IBIO (iBio) - Narx-foyda va o‘sish multiplikatori|Carisma Therapeutics Inc. (CARM) - PEG multiplikatori|Narxning foydaga va o‘sish sur’atiga nisbati XTL Biopharmaceuticals, Ltd.|O‘sishni hisobga olgan narx-foyda koeffitsiyenti BOLT (Bolt Bio)|PEG multiplikatori HCWB|APVO - O‘sish sur’atiga tuzatilgan narx-foyda|Narxning foydaga va o‘sish sur’atiga nisbati AIM ImmunoTech AIM|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Aditxt Inc. (ADTX)|GRI Bio Corp - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda XORTX Corp|Vyome Holdings Inc (HIND) - Narxning foydaga va o‘sish sur’atiga nisbati|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati REVB (revbiosciences.com)|Narx-foyda va o‘sish multiplikatori INDP|SCNI (Scinai Immunotherapeutics Ltd) - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|PEG multiplikatori CALI|AFMD - O‘sish sur’atiga tuzatilgan narx-foyda|Narxning foydaga va o‘sish sur’atiga nisbati Allakos ALLK|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti HOOK|IGMS - Narxning foydaga va o‘sish sur’atiga nisbati|ITOS (iTeos Therapeutics Inc) - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|OCEA: PEG multiplikatori|TC BioPharm Ltd (TCBP) - PEG multiplikatori|Narx-foyda va o‘sish multiplikatori THRD
